Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2

Interventions

pembrolizumab 40Gemcitabine 37Cisplatin 28Carboplatin 17enfortumab vedotin 15Nivolumab 15Mitomycin 14atezolizumab 13avelumab 12Docetaxel 10vinflunine 95-aminolevulinic acid hexyl ester 9apaziquone 8Paclitaxel 8BCG Vaccine 7durvalumab 6Fluorouracil 6Cystectomy 6sacituzumab govitecan 4Surgical Procedures, Operative 4Drug Therapy 4vofatamab 3valrubicin 3tisotumab vedotin 3erdafitinib 3cemiplimab 3belinostat 3Therapeutic Uses 3Ramucirumab 3Cystoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Urinary Bladder Neoplasms × VB4-845 × Clear all
NCT02449239 2023-07-24

VISTA

Sesen Bio, Inc.

Phase 3 Completed
133 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT00462488 2020-05-12

Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

Sesen Bio, Inc.

Phase 2 Completed
46 enrolled 10 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡